Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation.

The purpose of this work was to determine whether the outcome of patients with transformed indolent lymphoma improved if they, after R-chemo, also received upfront autologous stem-cell transplantation. Upfront autologous stem-cell transplant improved the outcome in sequential, but not composite/discordant TIL. The beneficial impact of ASCT was greater in patients, who were rituximab-naïve at transformation.